BRCA1 and breast carcinoma: Finally, we again sought to evaluate the translation of these findings to models of olaparib resistance in other clinically relevant tumors, and thus tested the sensitivity of an olaparib-resistant breast cancer PDX (CTG-0869, BRCA1/2 hemizygously deleted) to PRT543.